DAAM2 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q86T65 |
---|---|
Clone Names | 100617145 |
Peptide ID | 100617145 |
Gene ID | 23500 |
---|---|
Other Names | Disheveled-associated activator of morphogenesis 2, DAAM2, KIAA0381 |
Format | Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | DAAM2 |
---|---|
Synonyms | KIAA0381 |
Tissue Location | Expressed in most tissues examined. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abgent.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
DAAM2, dishevelled associated activator of morphogenesis 2, belongs to the formin homology family and contains a DAD (diaphanous autoregulatory) domain, an FH1 (formin homology 1) domain, an FH2 (formin homology 2) domain and a GBD/FH3 (Rho GTPase-binding/ formin homology 3) domain. It is a recently identified planar cell polarity (PCP) signaling molecule implicated in the regulation of cellular polarity, convergent extension, and invasion. It is suggested that DAAM2 is closely related to DAAM1 and hence along with DAAM1 it may also be required in Wnt/Fz signaling and activation of Rho and in regulating cytoskeleton architecture. It is expressed in most tissues examined.
References
Repapi, E., et al. Nat. Genet. 42(1):36-44(2010)Hirata, H., et al. Cancer 115(19):4488-4503(2009)Mungall, A.J., et al. Nature 425(6960):805-811(2003)Katoh, M., et al. Int. J. Oncol. 22(4):915-920(2003)Habas, R., et al. Cell 107(7):843-854(2001)

If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.